A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degrader

Journal:

Nature Communications

Published:

2026-03-25

DOI:

10.1038/s41467-026-70663-1

Affiliations:

15

Authors:

40

Go to article

Institutions	Authors	Share
AstraZeneca, United Kingdom (UK)	16.000000 16.000000	0.40
AstraZeneca Cambridge, United Kingdom (UK)	13.000000 13.000000	0.33
AstraZeneca Sweden, Sweden	8.000000	0.20
Pharmaron, China	2.000000	0.05
AstraZeneca United States, United States of America (USA)	1.000000	0.03

Interested in Pharmacology and Pharmaceutical Sciences?